Abstract P1-18-22: AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation
Seth A. Wander(Harvard University), Aditya Bardia(UCLA Health), Steven J. Isakoff(Harvard University), Maureen Beeler(Massachusetts General Hospital), Beverly Moy(Global Cancer Institute), Laura M. Spring(Massachusetts General Hospital), Taronish D. Dubash(Harvard University), Daniel A. Haber(Howard Hughes Medical Institute), Neelima Vidula(Harvard University), Dante Che(Harvard University), Leif W. Ellisen(Harvard University), Elene Viscosi(Center for Cancer Research), Jennifer C. Keenan(Massachusetts General Hospital), Shyamala Maheswaran(Massachusetts General Hospital), Dejan Juric(Massachusetts General Hospital), Jeffrey G. Supko(Harvard University), Douglas S. Micalizzi(Massachusetts General Hospital), Elizabeth L. Fisher(Massachusetts General Hospital), Rachel Hepp(Massachusetts General Hospital)
Cited by 1